01—Abstract
Summary
Summary of the 8-K filed July 6, 2026. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation reported in a Form 8-K dated July 6, 2026 that it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC.
The acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder, to Incyte's hematology portfolio. The company describes VGA039 as targeting Protein S to restore hemostasis, with potential to be the first once-monthly subcutaneous prophylactic therapy for VWD patients who currently require frequent intravenous infusions. Under the stock purchase agreement, Incyte acquired all outstanding shares of Vega Therapeutics for $1.25 billiona upfront.
Star Therapeutics is eligible to receive up to $750 millionb in additional payments upon the achievement of sales milestones. Incyte expects the transaction to be reflected as a one-time R&D expense in its third-quarter and full-year 2026 GAAP and non-GAAP results. VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration and has advanced into the Phase 3 VIVID-6 study, a global single-arm cross-over study of subcutaneous VGA039 prophylaxis in patients with all types of VWD.
02—Key points
Key Highlights
- Completed acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC, expanding Incyte's hematology portfolio
- VGA039, a Phase 3 monoclonal antibody targeting Protein S, is being added for von Willebrand disease, described as the most common inherited bleeding disorder
- Purchase price of $1.25 billion upfront, plus up to $750 million in additional payments tied to sales milestones
- VGA039 holds FDA Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations
- Company expects the transaction to be recorded as a one-time R&D expense in the third quarter and full-year 2026 GAAP and non-GAAP results
- Potential first once-monthly subcutaneous prophylactic therapy for VWD, versus current factor replacement therapies requiring multiple weekly IV infusions
- Phase 3 VIVID-6 study (NCT07115004) underway across all types of VWD, including patients with high disease burden
03—Questions
Frequently Asked Questions
What did Incyte acquire and for how much?
Incyte acquired all outstanding shares of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC, for $1.25 billion upfront. Star Therapeutics may also receive up to $750 million in additional payments upon achievement of sales milestones.
What is VGA039 and what condition does it target?
VGA039 is an investigational monoclonal antibody that modulates Protein S to improve hemostasis. It is in Phase 3 development for von Willebrand disease (VWD), which the company describes as the most common inherited bleeding disorder.
How will the acquisition affect Incyte's financial results?
Incyte expects the transaction to be reflected as a one-time R&D expense in its third-quarter and full-year 2026 GAAP and non-GAAP financial results.
What regulatory designations has VGA039 received?
VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration.
What is the potential advantage of VGA039 for patients?
If approved, VGA039 has the potential to be the first once-monthly subcutaneous prophylactic therapy for VWD. Current prophylaxis options require multiple intravenous infusions every week.
04—Continue